EGFR and non-small cell lung carcinoma: Non-small cell lung cancer-derived EVs containing amphiregulin, a ligand of epidermal growth factor receptor (EGFR), activate the EGFR pathway in pre-osteoclasts, which in turn promotes the expression level of receptor activator of nuclear factor kappa-B ligand (RANKL) [51].